Piramal Pharma Intrinsic Value
PPLPHARMA • Healthcare
Current Stock Price
₹141.04
Primary Intrinsic Value
₹122.75
Market Cap
₹186.7K Cr
-13.0%
Downside
Median Value
₹122.75
Value Range
₹72 - ₹128
Assessment
Trading Above Median Value
Safety Margin
-14.9%
PPLPHARMA Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹122.75 | ₹110.48 - ₹135.03 | -13.0% | Book Value/Share: ₹61.37, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹128.34 | ₹115.51 - ₹141.17 | -9.0% | Revenue/Share: ₹64.17, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹72.21 | ₹64.99 - ₹79.43 | -48.8% | EBITDA: ₹956.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹77.34 | ₹61.87 - ₹92.81 | -45.2% | CF Growth: 10.5%, Discount: 15% |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
PPLPHARMA Intrinsic Value Analysis
What is the intrinsic value of PPLPHARMA?
Based on our comprehensive analysis using 4 different valuation methods, the estimated intrinsic value of Piramal Pharma (PPLPHARMA) is ₹122.75 (median value). With the current market price of ₹141.04, this represents a -13.0% variance from our estimated fair value.
The valuation range spans from ₹72.21 to ₹128.34, indicating ₹72.21 - ₹128.34.
Is PPLPHARMA undervalued or overvalued?
Based on our multi-method analysis, Piramal Pharma (PPLPHARMA) appears to be trading above median value by approximately 13.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.53 | Industry Standard: 2.0+ | Above 1.5 | Measures short-term liquidity capacity |
| Return on Equity | -4.9% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 8.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.54x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Piramal Pharma
Additional stock information and data for PPLPHARMA
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹892 Cr | ₹648 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹1,005 Cr | ₹797 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹484 Cr | ₹-183 Cr | Positive Operating Cash Flow | 6/10 |
| March 2022 | ₹766 Cr | ₹-103 Cr | Positive Operating Cash Flow | 6/10 |
| March 2021 | ₹598 Cr | ₹-1,634 Cr | Positive Operating Cash Flow | 6/10 |